alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 41 studies in Brain scans and imaging published 2011 (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Default mode network connectivity in stable vs progressive mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2011-01-12

GOF indices were highest in normal controls, intermediate in MCI, and lowest in AD (p Conclusions fMRI connectivity indices distinguish patients with MCI who undergo cognitive decline and conversion to AD from those who remain stable over a 2- to 3-year follow-up period. 3 key findings →

Design: cross-sectional Participants: 68 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2011-04-27

Changes in functional connectivity in DLB indicate patterns of activation that are distinct from those seen in AD and may improve discrimination of DLB from AD and cognitively normal individuals. 3 key findings →

Design: longitudinal study Participants: 88 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International journal of geriatric psychiatry 2011-01-01

A framework for multi-centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. 4 key findings →

Design: longitudinal study Participants: 378 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Annals of neurology 2011-08-01

These findings suggest that CSF VILIP-1 and VILIP-1/Aβ42 offer diagnostic utility for early AD, and can predict future cognitive impairment in cognitively normal individuals similarly to tau and tau/Aβ42, respectively. 3 key findings →

Participants: 211 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America

✓ Peer-reviewed alzhub usefulness score 57 out of 100. NeuroImage 2011-07-01

The European Union AddNeuroMed program and the US-based Alzheimer Disease Neuroimaging Initiative (ADNI) are two large multi-center initiatives designed to collect and validate biomarker data for Alzheimer's disease (AD). 5 key findings →

Participants: 1,074 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2011-02-01

In older adults, variable agreement between in vivo imaging and CERAD NP score was observed. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Archives of neurology 2011-05-09

The INNOTEST and INNO-BIA CSF platforms perform equally well in identifying individuals with underlying amyloid plaque pathology. 2 key findings →

Participants: 103 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Brain : a journal of neurology 2011-09-09

The semantic and non-fluent/agrammatic variants are largely associated with frontotemporal lobar degeneration with TDP-43 and tau pathology, respectively. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 2011-12-21

This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting MCI outcome with clinically available MRI and CSF biomarkers

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurology 2011-10-12

Incorporating quantitative assessment of learning ability along with vMRI or CSF biomarkers in the clinical workup of MCI can provide critical information on risk of imminent conversion to AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2011-12-01

Since the introduction of amyloid imaging nearly 10 years ago, this technique has gained widespread use and acceptance. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The American journal of clinical nutrition 2011-11-09

Loss of cholinergic neurons is associated with impaired cognitive function, particularly memory loss and Alzheimer disease (AD). 3 key findings →

Participants: 1,391 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Classification of Alzheimer disease, mild cognitive impairment, and normal cognitive status with large-scale network analysis based on resting-state functional MR imaging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Radiology 2011-01-19

LSN analysis revealed that interconnectivity patterns of brain regions can be used to classify subjects with AD, those with aMCI, and CN subjects. 5 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neuroinformatics 2011-10-14

In this work we use a large scale regularization approach based on penalized logistic regression to automatically classify structural MRI images (sMRI) according to cognitive status. 3 key findings →

Participants: 98 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. NeuroImage 2011-11-30

The relation between pathology and cognitive dysfunction in dementia is still poorly understood, although disturbed communication between different brain regions is almost certainly involved. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011-01-13

A 7-min window, corresponding to minutes 1-8 (frames 5-15), produced the highest voxelwise correlation between (18)F-FDG and pPIB (R = 0.78 ± 0.05). 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neurobiology of aging 2011-08-20

Regional functional connectivity (FC) of 39 patients with Alzheimer's disease (AD), 23 patients with mild cognitive impairment (MCI), and 43 healthy elderly controls was studied using resting-state functional magnetic resonance imaging (rs-fMRI). 4 key findings →

Participants: 39 Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed